In conclusion, PPARγ agonists resensitize PTEN-deficient, EGFR-mutant NSCLC to gefitinib through a PPARγ-dependent induction of autophagy, supporting a biomarker-driven therapeutic strategy to overcome TKI resistance [83]. The gene discussed is PPARG; the disease is non-small cell lung carcinoma.